TD Cowen analyst Charles Rhyee raised the firm’s price target on GoodRx to $14 from $12 and keeps an Outperform rating on the shares. The firm said they remain positive and continue to believe ISP opportunity and its potential to drive upside to estimates could be significant. Cowen thinks 2024 guide could prove conservative as PBM partners ramp types of transactions and number of lives on ISP over 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GDRX:
